HYBRID EVENT: Join us in person in London, UK or attend virtually from anywhere.
Breakthroughs in molecular diagnostics, immunotherapy, and supportive care have redefined outcomes in pediatric oncology and hematology. From leukemias and lymphomas to rare solid tumors and inherited blood disorders, clinicians are now equipped with tools to personalize therapy while minimizing toxicities. Pediatric malignancies differ biologically from adult cancers, necessitating age-adapted protocols and close developmental surveillance. Advances such as CAR-T cell therapy, targeted agents, and precision diagnostics have improved survival while reducing late effects. In hematology, conditions like sickle cell anemia and thalassemia benefit from curative options like bone marrow transplantation and gene editing. A strong psychosocial and educational support system remains integral as children face long treatment journeys. Pediatric oncology and hematology continue to evolve with a focus on survivorship, quality of life, and equitable access to state-of-the-art care.
